NCT00040937 · OUTCOME

Overall Survival

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma · Source last updated 2016-12-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: proportion surviving at 4 years
Interval / dispersion: 95% Confidence Interval
Time frame: 4-7 years

Groups in this outcome

Treatment Arm

thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment Arm	142

Reported measurements

Source class 1

Values in proportion surviving at 4 years · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment Arm	.64	Not reported	.55	.74	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
55
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
74
group Description
The study was designed to have 82% power for detecting a 50% improvement in survival from a median of 4 years, as observed in SWOG S9321.
group Ids
OG000
non Inferiority Type
SUPERIORITY_OR_OTHER
param Type
4-yr survival (%)
param Value
64
statistical Method
Kaplan and Meier
tested Non Inferiority
false

Complete source fields

analyses

ci Lower Limit
55
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
74
group Description
The study was designed to have 82% power for detecting a 50% improvement in survival from a median of 4 years, as observed in SWOG S9321.
group Ids
OG000
non Inferiority Type
SUPERIORITY_OR_OTHER
param Type
4-yr survival (%)
param Value
64
statistical Method
Kaplan and Meier
tested Non Inferiority
false

classes

categories
measurements
group Id
OG000
lower Limit
.55
upper Limit
.74
value
.64

denoms

counts
group Id
OG000
value
142
units
Participants

dispersion Type

95% Confidence Interval

groups

description
thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
id
OG000
title
Treatment Arm

param Type

NUMBER

reporting Status

POSTED

time Frame

4-7 years

title

Overall Survival

type

PRIMARY

unit Of Measure

proportion surviving at 4 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice